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Oral Presentations 13with CD41T cells from RORgt-/- vsWT donors suggest a signif-
icant survival benefit for recipients of RORgt-/- T cells. In conclu-
sion, these data suggest that CD41 Th17 cells contribute to the
development of acute GVHD.
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IL13 12044 (ARG130GLN) ASSOCIATES WITH ACUTE AND CHRONIC
GRAFT-VERSUS-HOST DISEASE FOLLOWING HAEMATOPOIETIC STEM
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IL-13 is a T-helper 2 (Th2) cytokine that suppresses the cytotoxic
action of macrophages and inhibits the production of pro-inflam-
matory cytokines. A single nucleotide polymorphism (SNP) exists
within exon 4 of the IL13 gene at position 12044 which results in
an amino acid substitution (Arg130Gln). The high producer variant
(A allele) of this SNP, has been associated with several inflammatory
conditions, most notably asthma, and more recently IL-13 mixed
lymphocyte supernatant levels have been associated with aGvHD
in HSCT. Consequently the role of IL13 12044 SNP in HSCT
was examined in this investigation.
Polymorphism studies were carried out in a cohort of 923 HSCT
recipient and donors from 7 transplant centres across Europe. Gen-
otyping was performed using PCR and RFLP analysis. Univariant
(chi-squared) and multivariant (binary logistic regression) analyses
were performed to study associations and P values\0.05 were re-
garded as being statistically significant. Clinical factors such as re-
cipient age, gender mismatch (female donor/male recipient),
CMV status, stem cell source and treatment regimens were also in-
cluded in the analyses.
Multivariant analysis of the whole HSCT cohort demonstrated
that patients possessing the A allele were more susceptible to devel-
oping severe aGvHD (grades III-IV) (P5 0.028). Patients receiving
transplants from donors with the IL1312044 A allele were more at
risk of developing cGvHD (P 5 0.026). These associations re-
mained significant when the cohort was stratified for transplant
type (HLA-matched sibling andmatched unrelated donor) and con-
ditioning regimen (T replete vs deplete and reduced vs full intensity
conditioning). Significant associationswere also observed in a subset
of patients diagnosed with CML; HLA-matched sibling patients
possessing the IL13 12044 A allele were less likely to develop
cGvHD, whereas inMUD transplants donor possession of the A al-
lele was a risk for cGvHD. Depending on the subset analysis, clin-
ical factors, particularly peripheral blood stem cell transplants, were
significantly associated with GvHD.
To our knowledge this is the first investigation examining the role
of IL1312044 SNP in HSCT. The findings are extremely encour-
aging, indicating that IL1312044 SNP is associated with the devel-
opment of both aGvHD and cGvHD and consequently could
provide key pre-transplant information on GvHD prognosis.29
ADDITION OF ETANERCEPT TO METHYLPREDNISOLONE AS INITIAL
THERAPY FOR ACUTE GVHD RESULTS IN HIGH RESPONSE RATES AND
IMPROVED SURVIVAL
Levine, J.E., Paczesny, S., Mineishi, S., Braun, T., Choi, S.W.,
Hutchinson, R.J., Jones, D., Khaled, Y., Kitko, C.L., Bickley, D.,
Krijanovski, O., Reddy, P., Yanik, G., Ferrara, J.L.M. University of
Michigan, Ann Arbor, MI.
Standard therapy for GVHD, high dose steroids, results in com-
plete responses in only 35%of patients. Because tumor necrosis fac-
tor (TNF) is an important effector of GVHDwe treated 61 pts with
new onset GVHDwith methlyprednisolone 2 mg/kg/d plus etaner-
cept, a TNF inhibitor. All pts continued their prophylaxis agent,
usually tacrolimus, at therapeutic dosing.Etanercept was given subcutaneously 2 weekly for 8 wks at
a dose of 0.4 mg/kg/dose (max dose 25 mg). The outcomes in these
61 pts were compared to those of 99 contemporaneous pts with
GVHD whose initial therapy was steroids alone. Both groups of
pts were similar with respect to age, transplant conditioning inten-
sity, donor type, degree of HLA-match, and severity of GVHD at
onset. Pts who acheived CR by 4 wks did so without any second
line agents. Pts treated with etanercept plus steroids were signifi-
cantly more likely to achieve a complete response 4 wks later than
were pts treated with steroids alone [69% vs 33%, p\ 0.0001].
The benefit of etanercept persisted: at 12 wks after initiation of
GVHD treatment, 77% of etanercept plus steroids pts had achieved
CR compared to 50% of steroids alone pts (p5 0.0009). The supe-
riority of etanercept plus steroids over steroids alone was observed
in in all three target organs. Differences in steroid dosing did not
account for the difference in CR rate.
There was a trend for better survival at 6 mo following initiation
of GVHD treatment for the etanercept treated pts [p5 0.08] which
is explained by significantly superior survival in the unrelated donor
pts whoseGVHDwas treatedwith etanercept. Although related do-
nor pts who were treated with etanercept plus steroids were more
likely to be in CR at 4 wks [79% vs 39%, p 5 0.001], by 12 weeks
nearly equivalent proportions of pts in both groups achieved a CR
(etanercept plus steroids, 80%, steroids alone 70%) and 6 mo sur-
vival was similar. A greater proportion of unrelated donor pts
treated with etanercept were in CR at 4 wks [53% vs 26%, p 5
0.0005] but, unlike related donor pts, steroids alone pts who failed
to achieve a CR by 4 wks were likely to never achieve CR. This dif-
ference in overall CR rate translated into better survival six months
later [p 5 0.05].
Although not a randomized trial, these data strongly suggest that
etanercept plus steroids as initial therapy for acute GVHD results in
improved complete response rates compared to steroids alone and
may improve survival, especially for unrelated donor transplant pts.
Complete Response Rates at Four Weeks According to Treatment Group
Steroids Etanercept
alone plus steroids p valueOverall 33/99 (33%) 42/61 (69%) \0.0001
Skin 32/68 (47%) 30/37 (81%) 0.0008
Liver 3/15 (20%) 6/9 (67%) 0.03
GI 21/44 (48%) 29/37 (78%) 0.005
Presenting grade
Grade II 25/68 (37%) 31/40 (77%) 0.0001
Grade III/IV 8/31 (26%) 11/21 (52%) 0.0530
A FULLY-HUMAN CHIMERIC ANTIGEN RECEPTOR FOR REDIRECTING
SPECIFICITY OF T CELLS TO B-LINEAGE TUMORS
Manuri, P.R.1, Olivares, S.1, Dara, N.1, Dawson, M.J.1, Huls, H.1,
Lee, D.A.1, Shpall, E.J.2, Champlin, R.E.2, Cooper, L.J.N.1. 1Children’s
Cancer Hospital, U.T.M.D. Anderson Cancer Center, Houston, TX;
2U.T. MD Anderson Cancer Center, Hoouston, TX.
Adoptive therapy after allogeneic hematopoietic stem-cell trans-
plantation with ex vivo-expanded donor-derived tumor-specific T
cells to augment the graft-versus-leukemia (GVL) effect might be
used to reduce the incidence of leukemic relapse without exacerbat-
ing graft-versus-host disease. We previously showed that geneti-
cally modified peripheral- and umbilical cord blood-derived T
cells rendered specific for CD19, a molecule constitutively ex-
pressed on B-cell malignancies can augment GVL-effect. The re-
directed specificity was achieved by electro-transfer of a DNA
plasmid coding for the chimeric antigen receptor (CAR) that recog-
nizes CD19 via the scFv of a murine CD19-specific monoclonal an-
tibody (mAb) fused to T-cell activation endodomains. However,
